Effects of Shenxiang Suhe Pill on coronary heart disease complicated with nonalcoholic fatty liver disease: A case-control study

• Published in: Medicine (Baltimore) Vol. 101; no. 49; p. e31525
• Main Authors: Ni, Jie, Chen, Chen, Tang, Jiake, Hu, Siqi, You, Yao, Zhang, Shenghui, Jiang, Jingjie, Wang, Chunyi, Wen, Wen, Zhang, Xingwei, Wang, Mingwei
• Format: Journal Article
• Language: English
• Published: United States Lippincott Williams & Wilkins 09.12.2022
• Subjects: Alanine Transaminase - metabolism; C-Reactive Protein; Case-Control Studies; Cholesterol, HDL; Clinical Trial/Experimental Study; Humans; Liver - metabolism; Non-alcoholic Fatty Liver Disease - complications; Non-alcoholic Fatty Liver Disease - drug therapy; Non-alcoholic Fatty Liver Disease - metabolism; Triglycerides
• ISSN: 1536-5964; 0025-7974; 1536-5964
• DOI: 10.1097/MD.0000000000031525

To observe the clinical effect of Shenxiang Suhe Pill in the treatment of coronary heart disease (CHD) patients with nonalcoholic fatty liver disease (NAFLD). 56 CHD patients with NAFLD were randomly divided into an experimental group and control group. The control group was treated by conventional western medicines, while the experimental group was given Shenxiang Suhe Pill in addition to the treatment of the control group. Both groups were treated for 12 weeks. Before treatment and after 12 weeks of treatment, the clinical efficacy indices of the 2 groups were evaluated, including transient elastic B-ultrasound (Fibroscan), controlled attenuation parameter (CAP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), low density lipoprotein cholesterol, high density lipoprotein cholesterol, triglyceride (TG), total cholesterol, high sensitivity-reactive protein (hs-CRP) and lactate dehydrogenase (LDH). Compared with the control group, the CAP value of the experimental group decreased more significantly, and the severity classification of NAFLD was also significantly improved (P < .05). LDH and hs-CRP in the experimental group decreased after treatment (P < .05). TG and high density lipoprotein cholesterol indicators improved more in the experimental group than in the control group (P < .05). ALT and AST in neither group showed significant change (P > .05). Shenxiang Suhe Pills has a significant overall curative effect in the treatment of patients with CHD complicated with NAFLD. It can reduce liver lipid deposition, reduce the severity of NAFLD, and has lipid-lowering and anti -inflammatory effects.